
1. Cancers (Basel). 2018 Dec 5;10(12). pii: E490. doi: 10.3390/cancers10120490.

Obatoclax and Paclitaxel Synergistically Induce Apoptosis and Overcome Paclitaxel
Resistance in Urothelial Cancer Cells.

Jiménez-Guerrero R(1), Gasca J(2), Flores ML(3), Pérez-Valderrama B(4),
Tejera-Parrado C(5), Medina R(6), Tortolero M(7), Romero F(8), Japón MA(9)(10),
Sáez C(11)(12).

Author information: 
(1)Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del 
Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain. rjimenez-ibis@us.es.
(2)Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del 
Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain. jgasca-ibis@us.es.
(3)Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del 
Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain. mflores-ibis@us.es.
(4)Department of Oncology, Hospital Universitario Virgen del Rocío, 41013
Seville, Spain. bperezv@gmail.com.
(5)Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del 
Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain. ctejera-ibis@us.es.
(6)Department of Urology, Hospital Universitario Virgen del Rocío, 41013 Seville,
Spain. rantonio.medina.sspa@juntadeandalucia.es.
(7)Department of Microbiology, Faculty of Biology, Universidad de Sevilla, 41012 
Seville, Spain. torto@us.es.
(8)Department of Microbiology, Faculty of Biology, Universidad de Sevilla, 41012 
Seville, Spain. frport@us.es.
(9)Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del 
Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain. mjapon@cica.es.
(10)Department of Pathology, Hospital Universitario Virgen del Rocío, 41013
Seville, Spain. mjapon@cica.es.
(11)Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del
Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain. csaez1@us.es.
(12)Department of Pathology, Hospital Universitario Virgen del Rocío, 41013
Seville, Spain. csaez1@us.es.

Paclitaxel is a treatment option for advanced or metastatic bladder cancer after 
the failure of first-line cisplatin and gemcitabine, although resistance limits
its clinical benefits. Mcl-1 is an anti-apoptotic protein that promotes
resistance to paclitaxel in different tumors. Obatoclax, a BH3 mimetic of the
Bcl-2 family of proteins, antagonizes Mcl-1 and hence may reverse paclitaxel
resistance in Mcl-1-overexpressing tumors. In this study, paclitaxel-sensitive
5637 and -resistant HT1197 bladder cancer cells were treated with paclitaxel,
obatoclax, or combinations of both. Apoptosis, cell cycle, and autophagy were
measured by Western blot, flow cytometry, and fluorescence microscopy. Moreover, 
Mcl-1 expression was analyzed by immunohistochemistry in bladder carcinoma
tissues. Our results confirmed that paclitaxel alone induced Mcl-1 downregulation
and apoptosis in 5637, but not in HT1197 cells; however, combinations of
obatoclax and paclitaxel sensitized HT1197 cells to the treatment. In
obatoclax-treated 5637 and obatoclax + paclitaxel-treated HT1197 cells, the
blockade of the autophagic flux correlated with apoptosis and was associated with
caspase-dependent cleavage of beclin-1. Obatoclax alone delayed the cell cycle in
5637, but not in HT1197 cells, whereas combinations of both retarded the cell
cycle and reduced mitotic slippage. In conclusion, obatoclax sensitizes HT1197
cells to paclitaxel-induced apoptosis through the blockade of the autophagic flux
and effects on the cell cycle. Furthermore, Mcl-1 is overexpressed in many
invasive bladder carcinomas, and it is related to tumor progression, so Mcl-1
expression may be of predictive value in bladder cancer.

DOI: 10.3390/cancers10120490 
PMCID: PMC6316685
PMID: 30563080 

